Nuvation Bio Inc.
NUVB
$4.32
-$0.40-8.48%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,598.70% | 633.06% | 1,704.68% | 236.79% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,598.70% | 633.06% | 1,704.68% | 236.79% | -- |
| Cost of Revenue | 186.10% | -69.66% | 121.06% | 91.24% | -- |
| Gross Profit | 7,701.72% | 2,614.78% | 1,339.97% | 2,464.77% | -- |
| SG&A Expenses | 8.24% | 54.28% | 90.78% | 138.20% | 381.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.80% | 27.24% | 42.45% | 46.36% | 207.38% |
| Operating Income | 106.58% | 36.90% | -17.32% | -40.33% | -192.11% |
| Income Before Tax | 110.14% | 25.99% | -35.38% | 87.24% | -259.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 110.14% | 25.99% | -35.38% | 87.24% | -259.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 110.14% | 25.99% | -35.38% | 87.24% | -259.90% |
| EBIT | 106.58% | 36.90% | -17.32% | -40.33% | -192.11% |
| EBITDA | 107.53% | 37.65% | -16.61% | -40.30% | -191.42% |
| EPS Basic | 109.86% | 27.54% | -8.17% | 90.83% | -132.89% |
| Normalized Basic EPS | 109.87% | 27.59% | -8.18% | -13.30% | -132.94% |
| EPS Diluted | 109.69% | 27.54% | -8.17% | 90.83% | -128.57% |
| Normalized Diluted EPS | 109.87% | 27.59% | -8.18% | -13.30% | -132.94% |
| Average Basic Shares Outstanding | 2.58% | 2.20% | 25.16% | 39.23% | 54.58% |
| Average Diluted Shares Outstanding | 2.58% | 2.20% | 25.16% | 39.23% | 54.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |